Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia

Shiva Bamezai, Jing He, Pradeep Rajput, Deniz Sahin, Alex Jose Pulikkottil, Fabian Mohr, Mahalakshmi Naidu Vegi, Rana Pratap Singh, Deepshi Thakral, Ritu Gupta, Christian Buske, Vijay Pal Singh Rawat

Blood (2024) 144 (Supplement 1): 4114.

https://doi.org/10.1182/blood-2024-205890

Published: 2024

Journal Articles

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Lale Kostakoglu, MD MPH, Andrew Davies, MD PhD, Michael Herold, Wolfgang Hiddemann, Robert Marcus, Judith Trotman, FRACP, Andrea Knapp, Federico Mattiello, Tina G Nielsen, Deniz Sahin, Carol Ward, Anas Younes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134784

Published: 2020

Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman

Blood (2020) 135 (15): 1214–1218.

https://doi.org/10.1182/blood.2019001091

Published: 2020

Includes: Supplemental data

Journal Articles

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Lale Kostakoglu, MD MPH, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Andrea Knapp, PhD, Federico Mattiello, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Carol Ward, MSc, Anas Younes, MD

Blood (2019) 134 (Supplement_1): 489.

https://doi.org/10.1182/blood-2019-123626

Published: 2019

Journal Articles

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Skander Jemaa, MS, Jill Fredrickson, PhD, Alexandre Coimbra, PhD, Richard AD Carano, PhD, Tarec Christoffer C. El-Galaly, MD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Thomas Bengtsson, PhD, Alex de Crespigny, PhD

Blood (2019) 134 (Supplement_1): 4666.

https://doi.org/10.1182/blood-2019-124793

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Lale Kostakoglu, MD MPH, Paola Berchialla, PhD, Federico Dalmasso, PhD, Larry A Pierce, PhD, Umberto Vitolo, Maurizio Martelli, MD, Laurie H Sehn, MD, Marek Trněný, MD, Tina G Nielsen, MD PhD, Christopher R Bolen, PhD, Deniz Sahin, BSc, Calvin Lee, MD, Tarec Christoffer C. El-Galaly, MD, Federico Mattiello, PhD, Paul E Kinahan, PhD, Stephane Chauvie, PhD

Blood (2019) 134 (Supplement_1): 883.

https://doi.org/10.1182/blood-2019-123450

Published: 2019

Journal Articles

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Farheen Mir, MBBS, Sally F Barrington, Michel Meignan, Helen Brown, Tina Nielsen, Deniz Sahin, Judith Trotman

Blood (2018) 132 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2018-99-116686

Published: 2018

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Sally F Barrington, Judith Trotman, Deniz Sahin, David Belada, Andrew Davies, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Wolfgang Hiddemann, Robert Marcus, Tina Nielsen, Federico Mattiello, Harald Zeuner, Michel Meignan

Blood (2018) 132 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2018-99-117235

Published: 2018

Journal Articles

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H Sehn, MDMPH, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin, FRCPC, MD MS

Blood (2018) 132 (Supplement 1): 1605.

https://doi.org/10.1182/blood-2018-99-114913

Published: 2018

Journal Articles

TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib

Deniz Sahin, M.Sc, Shiva Bamezai, PhD, Fabio Ciccarone, PhD, Elena Fischbein, MSc, Fabian Mohr, PhD, Medhanie A. Mulaw, Jun.-Prof. Dr., Alex Pulikkottil Jose, M.Sc, Paola Caiafa, MD, Lüder-Hinrich Meyer, MD, Klaus-Michael Debatin, Prof. Dr., Geertruy te Kronnie, PhD, Konstanze Döhner, Hartmut Döhner, Prof. Dr., Michaela Feuring-Buske, PD Dr., Christian Buske, Vijay P.S. Rawat, PhD

Blood (2016) 128 (22): 737.

https://doi.org/10.1182/blood.V128.22.737.737

Published: 2016

Journal Articles

The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia

Shiva Bamezai, PhD, Jing He, Dr., Deniz Sahin, M.Sc, Fabian Mohr, PhD, Fabio Ciccarone, PhD, Naidu M Vegi, PhD, Alex Pulikkottil Jose, M.Sc, Medhanie A. Mulaw, Jun.-Prof. Dr., Paola Caiafa, MD, Konstanze Döhner, Hartmut Döhner, MD, Michaela Feuring-Buske, PD Dr., Christian Buske, Vijay P.S. Rawat, PhD

Blood (2016) 128 (22): 4063.

https://doi.org/10.1182/blood.V128.22.4063.4063

Published: 2016

NARROW

An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia

Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

TET1 Promotes Leukemic Growth in T-ALL Via Maintenance of 5-Hydroxymethylation Marks and Can be Antagonized By the PARP Inhibitor Olaparib

The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only